58 related articles for article (PubMed ID: 30409854)
1. Brain Tumor Imaging without Gadolinium-based Contrast Agents: Feasible or Fantasy?
Wamelink IJHG; Azizova A; Booth TC; Mutsaerts HJMM; Ogunleye A; Mankad K; Petr J; Barkhof F; Keil VC
Radiology; 2024 Feb; 310(2):e230793. PubMed ID: 38319162
[TBL] [Abstract][Full Text] [Related]
2. Detection of pathological contrast enhancement with synthetic brain imaging from quantitative multiparametric MRI.
Donatelli G; Migaleddu G; Cencini M; Cecchi P; D'Amelio C; Peretti L; Buonincontri G; Tosetti M; Costagli M; Cosottini M
J Neuroimaging; 2024 Apr; ():. PubMed ID: 38590085
[TBL] [Abstract][Full Text] [Related]
3. Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging.
Bennett S; Verry C; Kaza E; Miao X; Dufort S; Boux F; Crémillieux Y; de Beaumont O; Le Duc G; Berbeco R; Sudhyadhom A
Sci Rep; 2024 May; 14(1):11959. PubMed ID: 38796495
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Autopsy-Validated Tumor Probability Maps Identify Glioma Invasion Beyond Contrast Enhancement.
Bobholz SA; Lowman AK; Connelly JM; Duenweg SR; Winiarz A; Nath B; Kyereme F; Brehler M; Bukowy J; Coss D; Lupo JM; Phillips JJ; Ellingson BM; Krucoff MO; Mueller WM; Banerjee A; LaViolette PS
Neurosurgery; 2024 Mar; ():. PubMed ID: 38501824
[TBL] [Abstract][Full Text] [Related]
5. A new candidate agent for fluorescence guided neurosurgery produces high, persistent tumor contrast shortly after administration.
Scorzo AV; Byrd BK; Strawbridge RR; Davis SC
Proc SPIE Int Soc Opt Eng; 2023; 12361():. PubMed ID: 38765853
[TBL] [Abstract][Full Text] [Related]
6. Letter to the Editor. Is postgadolinium FLAIR imaging a reliable biomarker of blood-brain barrier disruption?
Mamourian AC
J Neurosurg; 2021 Nov; 136(4):1209-1210. PubMed ID: 34767530
[No Abstract] [Full Text] [Related]
7. Toward deep learning replacement of gadolinium in neuro-oncology: A review of contrast-enhanced synthetic MRI.
Moya-Sáez E; de Luis-García R; Alberola-López C
Front Neuroimaging; 2023; 2():1055463. PubMed ID: 37554645
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance relaxometry in quantitative imaging of brain gliomas: A literature review.
Chekhonin IV; Cohen O; Otazo R; Young RJ; Holodny AI; Pronin IN
Neuroradiol J; 2024 Jun; 37(3):267-275. PubMed ID: 37133228
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.
Cudalbu C; Bady P; Lai M; Xin L; Gusyatiner O; Hamou MF; Lepore M; Brouland JP; Daniel RT; Hottinger AF; Hegi ME
Acta Neuropathol Commun; 2021 Aug; 9(1):133. PubMed ID: 34348785
[TBL] [Abstract][Full Text] [Related]
10. Quantitative MRI using relaxometry in malignant gliomas detects contrast enhancement in peritumoral oedema.
Blystad I; Warntjes JBM; Smedby Ö; Lundberg P; Larsson EM; Tisell A
Sci Rep; 2020 Oct; 10(1):17986. PubMed ID: 33093605
[TBL] [Abstract][Full Text] [Related]
11. Brain Tumor-Enhancement Visualization and Morphometric Assessment: A Comparison of MPRAGE, SPACE, and VIBE MRI Techniques.
Danieli L; Riccitelli GC; Distefano D; Prodi E; Ventura E; Cianfoni A; Kaelin-Lang A; Reinert M; Pravatà E
AJNR Am J Neuroradiol; 2019 Jul; 40(7):1140-1148. PubMed ID: 31221635
[TBL] [Abstract][Full Text] [Related]
12. Quantitative MRI for analysis of peritumoral edema in malignant gliomas.
Blystad I; Warntjes JBM; Smedby Ö; Lundberg P; Larsson EM; Tisell A
PLoS One; 2017; 12(5):e0177135. PubMed ID: 28542553
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement.
Zhou J; Zhu H; Lim M; Blair L; Quinones-Hinojosa A; Messina SA; Eberhart CG; Pomper MG; Laterra J; Barker PB; van Zijl PC; Blakeley JO
J Magn Reson Imaging; 2013 Nov; 38(5):1119-28. PubMed ID: 23440878
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence.
Kanal E; Maravilla K; Rowley HA
AJNR Am J Neuroradiol; 2014 Dec; 35(12):2215-26. PubMed ID: 24852287
[TBL] [Abstract][Full Text] [Related]
15. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.
Ellingson BM; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Mar; 20(4):457-471. PubMed ID: 29040703
[TBL] [Abstract][Full Text] [Related]
16. Synthesizing a Contrast-Enhancement Map in Patients with High-Grade Gliomas Based on a Postcontrast MR Imaging Quantification Only.
Warntjes M; Blystad I; Tisell A; Larsson EM
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2194-2199. PubMed ID: 30409854
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
